The FDA Professes to Support The Development of mHealth Apps

The FDA Professes to Support The Development of mHealth AppsThere are strong feelings of both acceptance and opposition in the healthcare industry when it comes to the adoption of mHealth apps. However, the term “mHealth” is so broad that it can be used to describe technology that is beneficial individually to patients and healthcare professionals, as well as patients and healthcare professionals.

Regardless of the pros and cons, mHealth apps continue to be developed at a feverish pace and the FDA is taking notice. Recently the FDA publicly shared datasets and reports with the intent of helping mHealth app developers create and improve their heath-centric apps. This publicly shared information is called the OpenFDA initiative.

“These reports will be available in their entirety so that software developers can build tools to help signal potential safety information, derive meaningful insights and get information to consumers and healthcare professionals in a timely manner,” says the FDA’s Chief Health Informatics Officer, Taha Kass-Hout.

The reports and datasets are designed not only to be an informative tool for developers, but for healthcare professionals across the board, and the general public who will benefit from advances in improved mHealth technology.

As studies and opinion polls from across the healthcare industry continue to affirm, mHealth apps have the potential to improve patient care, healthcare provider efficiency, and reduce the risk for medical errors by ensuring that all information is in one easy to access place.

The mHealth industry already generates well over $2.4 billion in annual revenue, which is expected to grow to over $26 billion within the next three years.

This post was written by:

- who has written 2292 posts on mHealthWatch.

Contact the author